Trial NCT04907331; 2021-002171-19
Publication Bánki Z, EBioMedicine, 2022
Primary outcome on the report: Levels of neutralizing antibodies against wild type and immune escape variants.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.